TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24383930

Group type: EXPERIMENTAL
Intervention: IL-1 receptor antagonist (IL-1Ra) 500 mg bolus, then 10 mg/kg/hr infusion for 24 hours
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 22854400

Group type: EXPERIMENTAL
Intervention: High-energy density preload (0.97 kcal/g)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Low-energy density preload (0.57 kcal/g)
Number of subjects: 47

Group type: COMPARATOR
Intervention: No preload consumed
Number of subjects: 47
Study: 20689391

Group type: EXPERIMENTAL
Intervention: Physical activity intervention using a new PA questionnaire and accelerometry
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 17097152

Group type: EXPERIMENTAL
Intervention: Xylitol 5g three times-a-day (TID)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Xylitol 7.5g once daily (QD)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 16109574

Group type: EXPERIMENTAL
Intervention: Esomeprazole-based therapy (20 mg esomeprazole, 1000 mg amoxicillin, 500 mg clarithromycin twice daily for 7 days)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Omeprazole-based therapy (20 mg omeprazole, 1000 mg amoxicillin, 500 mg clarithromycin twice daily for 7 days)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Esomeprazole-based therapy
Number of subjects: 104

Group type: COMPARATOR
Intervention: Omeprazole-based therapy
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Both therapies
Number of subjects: 104
Study: 12217302

Group type: EXPERIMENTAL
Intervention: Goserelin
Number of subjects: 320

Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 320
Study: 9469333

Group type: EXPERIMENTAL
Intervention: Vitamin E 800 IU daily
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 7824138

Group type: EXPERIMENTAL
Intervention: Left-hemisphere anesthesia (Wada test)
Number of subjects: 54
Study: 2228634

Group type: EXPERIMENTAL
Intervention: Self-help/minimal intervention strategies for smoking cessation
Number of subjects: 0
Study: 89336

Group type: EXPERIMENTAL
Intervention: Short-term protein restriction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Short-term energy restriction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dietary protein changes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dietary energy changes
Number of subjects: 0
Study: 30953416

Group type: EXPERIMENTAL
Intervention: Self-adhesive flowable composite (Vetise Flow, VF) with self-etching primer (SP)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Conventional flowable composite (Clearfil Magesty Flow, CM) with self-etching primer (SP)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Conventional flowable composite (Clearfil Magesty Flow, CM)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Self-adhesive flowable composite (Vetise Flow, VF)
Number of subjects: 84
Study: 28339996

Group type: EXPERIMENTAL
Intervention: Triple P-Positive Parenting Program
Number of subjects: 107

Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 107
Study: 25951307

Group type: EXPERIMENTAL
Intervention: MTAD
Number of subjects: 60

Group type: COMPARATOR
Intervention: 1% NaOCl
Number of subjects: 60

Group type: COMPARATOR
Intervention: Comparison of MTAD vs 1% NaOCl
Number of subjects: 60
Study: 23756608

Group type: EXPERIMENTAL
Intervention: Open-label LDX (20-70 mg/day)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Open-label LDX
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: LDX
Number of subjects: 92
Study: 21700105

Group type: EXPERIMENTAL
Intervention: Corneal collagen crosslinking (CXL)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 71
Study: 19840500

Group type: EXPERIMENTAL
Intervention: Immediate post space preparation using LA Axxess burs
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Delayed post space preparation using LA Axxess burs
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Immediate post space preparation using heated pluggers
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Delayed post space preparation using heated pluggers
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Immediate post space preparation using solvent delivered with a hand file
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Delayed post space preparation using solvent delivered with a hand file
Number of subjects: 66

Group type: COMPARATOR
Intervention: Positive control (instrumented but not obturated)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Negative control (instrumented, obturated and sealed with Cavit)
Number of subjects: 66
Study: 16387410

Group type: EXPERIMENTAL
Intervention: Lich-Gregoir reimplantation
Number of subjects: 44

Group type: COMPARATOR
Intervention: Politano-Leadbetter technique
Number of subjects: 44
Study: 14762667

Group type: EXPERIMENTAL
Intervention: 1.8 Hz vibration (group A)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 6 Hz vibration (group B)
Number of subjects: 60

Group type: COMPARATOR
Intervention: No vibration (group C)
Number of subjects: 60
Study: 11028730

Group type: EXPERIMENTAL
Intervention: 0.2% ropivacaine
Number of subjects: 30

Group type: COMPARATOR
Intervention: 0.2% bupivacaine
Number of subjects: 30
Study: 9305328

Group type: EXPERIMENTAL
Intervention: Intravenous levodopa (LD) administered over a wide dose range
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Higher levodopa doses
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Smaller, more frequent levodopa doses
Number of subjects: 25
Study: 8280213

Group type: EXPERIMENTAL
Intervention: Guidelines for general practice management and referral of infertile couples
Number of subjects: 200
Study: 3539632

Group type: EXPERIMENTAL
Intervention: Intravenous infusions of prostacyclin
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo (solvent) infusions
Number of subjects: 9
Study: 30222916

Group type: EXPERIMENTAL
Intervention: Lorcaserin
Number of subjects: 137

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 137
Study: 26711715

Group type: EXPERIMENTAL
Intervention: Rectal indomethacin
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study: 24555909

Group type: EXPERIMENTAL
Intervention: Ultrasonic device (UC)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Standard electric dissection (ELC)
Number of subjects: 43
Study: 22694484

Group type: EXPERIMENTAL
Intervention: Sumatriptan iontophoretic transdermal system
Number of subjects: 469

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 469
Study: 19910265

Group type: EXPERIMENTAL
Intervention: Ketamine 1mg/kg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Nitrous oxide 60%
Number of subjects: 16

Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Nitrogen (Control)
Number of subjects: 16
Study: 18506661

Group type: EXPERIMENTAL
Intervention: Computed tomography (CT) screening for lung cancer
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual clinical practice
Number of subjects: 0
Study: 15925046

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 67

Group type: COMPARATOR
Intervention: Betamethasone
Number of subjects: 67
Study: 12720115

Group type: EXPERIMENTAL
Intervention: EMD plus selective COX-2 inhibitor (rofecoxib 12.5 mg twice daily for 14 days)
Number of subjects: 22

Group type: COMPARATOR
Intervention: EMD alone
Number of subjects: 22
Study: 11093293

Group type: EXPERIMENTAL
Intervention: Low-fat high simple carbohydrate group
Number of subjects: 398

Group type: EXPERIMENTAL
Intervention: Low-fat high complex carbohydrate group
Number of subjects: 398

Group type: COMPARATOR
Intervention: Control diet group
Number of subjects: 398

Group type: COMPARATOR
Intervention: Seasonal control group
Number of subjects: 398
Study: 8857675

Group type: EXPERIMENTAL
Intervention: Ultrafiltration
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control (no ultrafiltration)
Number of subjects: 18
Study: 1514343

Group type: EXPERIMENTAL
Intervention: Alfentanil 10 micrograms.kg‐1
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Alfentanil 15 micrograms.kg‐1
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Alfentanil 20 micrograms.kg‐1
Number of subjects: 100

Group type: COMPARATOR
Intervention: Lignocaine 10 mg mixed with propofol
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Alfentanil
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Alfentanil and propofol
Number of subjects: 100
Study: 6395527

Group type: EXPERIMENTAL
Intervention: 6 dragées (drg.) Actovegin
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 9 dragées (drg.) Actovegin
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 30607535

Group type: EXPERIMENTAL
Intervention: Rotigotine (PD-Rot)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo (PD-Pla)
Number of subjects: 42
Study: 28056410

Group type: EXPERIMENTAL
Intervention: 10 minutes of intense exercise
Number of subjects: 62

Group type: COMPARATOR
Intervention: Slow walking (control condition)
Number of subjects: 62
Study: 27298402

Group type: EXPERIMENTAL
Intervention: Histologic transformation (HT)
Number of subjects: 1018

Group type: EXPERIMENTAL
Intervention: Salvage treatment for HT
Number of subjects: 1018

Group type: EXPERIMENTAL
Intervention: Overall survival for patients with HT
Number of subjects: 1018

Group type: EXPERIMENTAL
Intervention: Autologous stem cell transplantation for HT
Number of subjects: 1018
Study: 26287058

Group type: EXPERIMENTAL
Intervention: Educational materials regarding living kidney donation (n = 78)
Number of subjects: 149

Group type: COMPARATOR
Intervention: No educational materials regarding living kidney donation (n = 71)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Acquaintance with a transplant recipient
Number of subjects: 149
Study: 21807984

Group type: EXPERIMENTAL
Intervention: Very Early and Frequent Mobilization (VEM)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 71
Study: 19127436

Group type: EXPERIMENTAL
Intervention: Indinavir-loaded microparticles (15% drug load)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Indinavir-loaded microparticles (90% drug load)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Indinavir-loaded microparticles
Number of subjects: 10
Study: 17609916

Group type: EXPERIMENTAL
Intervention: Glossy Ganoderma Decoction (GGD) combined with conventional treatment (penicillin and reduced glutathione)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Conventional treatment (penicillin and reduced glutathione) alone
Number of subjects: 23
Study: 15055896

Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 40
Study: 11829202

Group type: EXPERIMENTAL
Intervention: Fluconazole (150 mg weekly)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study: 9625398

Group type: EXPERIMENTAL
Intervention: Garlic powder (900 mg/d)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 7836218

Group type: EXPERIMENTAL
Intervention: Buffer treatment (alkali loading) during constant-intensity exercise at 85% of maximal exertion
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo during constant-intensity exercise at 85% of maximal exertion
Number of subjects: 7
Study: 3254768

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Bendroflumethiazide
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 35
Study: 31539358

Group type: EXPERIMENTAL
Intervention: Life skills training with health literacy strategies
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 96
Study: 28698991

Group type: EXPERIMENTAL
Intervention: Thulium vapoenucleation of the prostate (ThuVEP)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Holmium laser enucleation of the prostate (HoLEP)
Number of subjects: 94
Study: 25627640

Group type: EXPERIMENTAL
Intervention: Resistance Training (RT)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Whole-Body Vibration Training associated with Resistance Training (WBV + RT)
Number of subjects: 15
Study: 24028076

Group type: EXPERIMENTAL
Intervention: Ganirelix started on day 5 of ovarian stimulation
Number of subjects: 2096

Group type: EXPERIMENTAL
Intervention: Ganirelix started on day 6 of ovarian stimulation
Number of subjects: 2096

Group type: COMPARATOR
Intervention: No LH rise prior to ganirelix treatment
Number of subjects: 2096

Group type: COMPARATOR
Intervention: No LH rise during ganirelix treatment
Number of subjects: 2096

Group type: EXPERIMENTAL
Intervention: Women with LH rise during ganirelix treatment
Number of subjects: 2096
Study: 21255534

Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg and ASA 325 mg in a single capsule
Number of subjects: 49

Group type: COMPARATOR
Intervention: Separate monotherapies of esomeprazole 40 mg and ASA 325 mg
Number of subjects: 49
Study: 19485593

Group type: EXPERIMENTAL
Intervention: Universal intervention (student curriculum and teacher training)
Number of subjects: 5581

Group type: EXPERIMENTAL
Intervention: Selective intervention (family intervention for high aggression students)
Number of subjects: 5581

Group type: EXPERIMENTAL
Intervention: Combined intervention
Number of subjects: 5581

Group type: COMPARATOR
Intervention: No-intervention control
Number of subjects: 5581
Study: 16481959

Group type: EXPERIMENTAL
Intervention: Manual Cobb angle
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Digitized Cobb angle
Number of subjects: 120

Group type: COMPARATOR
Intervention: Debrunner kyphometer
Number of subjects: 120
Study: 16351536

Group type: EXPERIMENTAL
Intervention: Queensland Case Conferences trial (QCC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Palliative Care Trial (PCT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: PCT
Number of subjects: 0

Group type: COMPARATOR
Intervention: QCC
Number of subjects: 0

Group type: COMPARATOR
Intervention: Both studies
Number of subjects: 0
Study: 12490865

Group type: EXPERIMENTAL
Intervention: Parathyroidectomy (group A)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Observation (group B)
Number of subjects: 50
Study: 9534693

Group type: EXPERIMENTAL
Intervention: 3D T2* MRI
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Gadolinium enhanced 2D T1 MRI
Number of subjects: 20

Group type: COMPARATOR
Intervention: CT myelography
Number of subjects: 20
Study: 7630673

Group type: EXPERIMENTAL
Intervention: Dexamethasone (0.6 mg/kg)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 38
Study: 2651244

Group type: EXPERIMENTAL
Intervention: Beta-interferon gel (100,000 IU/g), self-administered 4 times daily to the affected areas.
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo (in half the patients, double-blind, cross-over study).
Number of subjects: 28
Study: 174489

Group type: EXPERIMENTAL
Intervention: Adenine arabinoside ointment
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 31825248

Group type: EXPERIMENTAL
Intervention: SAR341402 insulin aspart
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: NovoLog® (US-sourced insulin aspart)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: NovoRapid® (EU-sourced insulin aspart)
Number of subjects: 30
Study: 30784040

Group type: EXPERIMENTAL
Intervention: Headache-Specific Locus of Control scale
Number of subjects: 695
Study: 28673747

Group type: EXPERIMENTAL
Intervention: Telemedicine screening intervention in primary care offices and Federally Qualified Health Centers
Number of subjects: 906
Study: 25539467

Group type: EXPERIMENTAL
Intervention: Corticosteroid withdrawal (CW)
Number of subjects: 196

Group type: COMPARATOR
Intervention: Corticosteroid continuation (CC)
Number of subjects: 196
Study: 21775111

Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment (Losartan)
Number of subjects: 875
Study: 21669959

Group type: EXPERIMENTAL
Intervention: Household smoking ban
Number of subjects: 99
Study: 19635145

Group type: EXPERIMENTAL
Intervention: Powdered supplement (30 mg iron as micronized dispersible ferric pyrophosphate, 600 mug folic acid)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Tablet supplement (27 mg iron from ferrous fumarate, 1000 mug folic acid)
Number of subjects: 18
Study: 16749412

Group type: EXPERIMENTAL
Intervention: Lornoxicam (8 mg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ketoprofen (100 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 60
Study: 15243305

Group type: EXPERIMENTAL
Intervention: L-NMMA (0.8 mg/min/dL)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: L-NMMA (1.6 mg/min/dL)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: L-NMMA (EC50)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: L-NMMA (Maximal vasoconstrictive response)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Blood pressure
Number of subjects: 17
Study: 11336846

Group type: EXPERIMENTAL
Intervention: Ultrasound screening for AAA
Number of subjects: 12203
Study: 9271777

Group type: EXPERIMENTAL
Intervention: GHRH (50 micrograms hourly between 22.00 h and 1.00 h, 4 x 50 micrograms)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: GHRH (after priming)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study: 8188163

Group type: EXPERIMENTAL
Intervention: Interferon-alpha 2a high dose (18 MU/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Interferon-alpha 2a low dose (3 MU/day)
Number of subjects: 0
Study: 2897008

Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Number of subjects: 23

Group type: COMPARATOR
Intervention: Penicillin
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Ceftriaxone 4 g/day
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Ceftriaxone 2 g/day
Number of subjects: 23
Study: 29520533

Group type: EXPERIMENTAL
Intervention: Acupuncture (AC) - twice weekly manual acupuncture over six weeks
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Acupuncture (AC)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Usual care wait-list control (WL)
Number of subjects: 82
Study: 27943570

Group type: EXPERIMENTAL
Intervention: Telephone-Delivered Cognitive Behavioural Therapy (T-CBT)
Number of subjects: 118

Group type: COMPARATOR
Intervention: CBT face to face treatment as usual (TAU-CBT)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Both T-CBT and TAU-CBT
Number of subjects: 118

Group type: COMPARATOR
Intervention: TAU-CBT
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: T-CBT
Number of subjects: 118
Study: 26181225

Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS) over the auditory cortex
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (normal hearing)
Number of subjects: 19
Study: 22791597

Group type: EXPERIMENTAL
Intervention: Transvaginal sonography (TVS)
Number of subjects: 50639
Study: 21672205

Group type: EXPERIMENTAL
Intervention: Cognitive behaviour therapy (CBT) - 5 to 10 sessions based on the Salkovskis/Warwick model.
Number of subjects: 466

Group type: COMPARATOR
Intervention: Control group - standard care including clinical assessment, appropriate tests, and reassurance.
Number of subjects: 466
Study: 18490527

Group type: EXPERIMENTAL
Intervention: Abciximab (glycoprotein IIb/IIIa inhibitor)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Stenting alone
Number of subjects: 100

Group type: COMPARATOR
Intervention: Stenting with embolic protection (Angioguard)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Combination therapy (Stenting with both embolic protection and abciximab)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Embolic protection (Angioguard)
Number of subjects: 100
Study: 16448810

Group type: EXPERIMENTAL
Intervention: CPAP with distal oxygen connection point
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: NIPPV
Number of subjects: 10

Group type: COMPARATOR
Intervention: CPAP
Number of subjects: 10
Study: 12973486

Group type: EXPERIMENTAL
Intervention: 100 mg lamivudine daily for 6 months
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 11019866

Group type: EXPERIMENTAL
Intervention: Ethanol-assisted mechanical debridement
Number of subjects: 9

Group type: COMPARATOR
Intervention: Transepithelial phototherapeutic keratectomy (PTK)
Number of subjects: 9
Study: 8712035

Group type: EXPERIMENTAL
Intervention: Knowledge of Results (KR) group practiced 200 trials a day for 5 days, then 1 day without KR.
Number of subjects: 200

Group type: COMPARATOR
Intervention: No Knowledge of Results (no-KR) group practiced 200 trials for one day.
Number of subjects: 200
Study: 1330079

Group type: EXPERIMENTAL
Intervention: Gamimmune N
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Immune Globulin Intravenous
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Gammagard
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Sandoglobulin
Number of subjects: 42
Study: 3882615

Group type: EXPERIMENTAL
Intervention: iohexol
Number of subjects: 363

Group type: COMPARATOR
Intervention: iopamidol
Number of subjects: 363

Group type: EXPERIMENTAL
Intervention: Both iohexol and iopamidol
Number of subjects: 363
Study: 30821515

Group type: EXPERIMENTAL
Intervention: FES-Cycling
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo-FES
Number of subjects: 8
Study: 29252011

Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy (MET) plus Family Check-Up (FCU)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Psychoeducation (PE) condition
Number of subjects: 69
Study: 26695436

Group type: EXPERIMENTAL
Intervention: NB‐UVB therapy plus intradermal injection of PRP every 2 weeks for 4 months
Number of subjects: 60

Group type: COMPARATOR
Intervention: NB‐UVB alone (control side)
Number of subjects: 60
Study: 24648359

Group type: EXPERIMENTAL
Intervention: Mindfulness education program (8 sessions of 2.5 hours per week plus a 1-day session of 8 hours)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 68
Study: 22187107

Group type: EXPERIMENTAL
Intervention: Joint attention intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Symbolic play intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 19763634

Group type: EXPERIMENTAL
Intervention: Trabecular Metal (TM)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Smith-Robinson (SR) with autograft
Number of subjects: 80